Elevated levels of the gut hormone GLP-1 and its receptor have been identified as potential exacerbators of brain inflammation in patients with neuromyelitis optica spectrum disorder (NMOSD), shedding light on the intricate interplay between gut hormones and autoimmune conditions.
Research unveiled at the 150th Annual Meeting of the American Neurological Association indicates that heightened levels of the gut hormone glucagon-like peptide-1 (GLP-1) could contribute to increased brain inflammation in individuals grappling with NMOSD, a rare autoimmune disorder characterized by spinal cord and optic nerve inflammation.
GLP-1, a natural gut hormone released post-meal, is renowned for its blood sugar regulation, digestion modulation, and appetite control properties. While GLP-1-based drugs are commonly employed to aid weight loss and manage diabetes, this study suggests a potential dark side in the context of NMOSD.
The study suggests a plausible association between GLP-1 and its receptor, GLP-1R, and the development of area postrema syndrome (APS), a condition marked by severe nausea and vomiting commonly experienced by NMOSD patients. Up to 10% of NMOSD patients exhibit APS as their initial symptom, with 30% eventually developing it during the course of the disease.
Dr. Lingfei Yang, a researcher from the First Affiliated Hospital of Zhengzhou University, China, emphasized the paradoxical nature of GLP-1 in NMOSD, stating, “We found that this hormone, which is usually helpful in other conditions, can actually make things worse for people with APS by overstimulating certain brain cells.”
The study revealed significantly elevated levels of both GLP-1 and GLP-1R in patients with APS compared to those with NMOSD alone. Additionally, experiments on mice exhibiting APS-like symptoms showcased a decrease in brain overactivity upon administration of Exendin-(9-39), a drug known to block GLP-1R.
Dr. Yang cautioned against blanket assumptions, noting, “Our findings don’t mean that GLP-1 drugs are automatically harmful or cause inflammation on their own. Instead, they may trigger stronger reactions in people who already have inflammation in the brain, like those with NMOSD.”
NMOSD, affecting approximately 1 in 100,000 individuals globally, disproportionately impacts women, with Asian and African American populations exhibiting a higher predisposition. The debilitating symptoms of NMOSD, including pain, vision loss, and paralysis, stem from the immune system’s assault on the optic nerves, spinal cord, and brain regions.
Diagnosing NMOSD can be challenging, with a significant subset of patients initially misdiagnosed with multiple sclerosis due to symptom overlap. A blood test detecting anti-aquaporin-4 (AQP4-IgG) antibodies, present in up to 80% of NMOSD cases, aids in accurate diagnosis.
While no definitive cure exists for NMOSD, symptom management is achievable through treatments like steroids, immunosuppressants, and biologic drugs, offering some respite to affected individuals.
The presentation by Dr. Yang, titled ‘GLP-1/GLP-1R-mediated Glycolytic Reprogramming Drives Area Postrema Neuronal Hyperactivity in Neuromyelitis Optica Spectrum Disorder,’ at the American Neurological Association’s 150th Annual Meeting underscores the imperative of further research to elucidate the nuanced effects of GLP-1 in autoimmune disorders.
In conclusion, the intricate relationship between GLP-1 levels and brain inflammation in NMOSD unveils a novel facet of autoimmune pathophysiology, underscoring the need for tailored therapeutic approaches in this patient population.
- GLP-1 and GLP-1R may exacerbate brain inflammation in NMOSD
- APS, characterized by severe nausea, linked to elevated GLP-1 levels
- NMOSD diagnosis challenging; blood test crucial for accurate identification
- No definitive cure for NMOSD; symptom management pivotal
- Further research essential to comprehend GLP-1’s role in autoimmune disorders
Read more on managedhealthcareexecutive.com